In November 2025, the Vietnam Lung Association, in collaboration with the Central Lung Hospital, the National Tuberculosis Program, and Imexpharm, organized the Vila 2025 National Lung Disease Scientific Conference in Can Tho. Held in a hybrid format, combining in-person and online participation, the event attracted over 1,000 respiratory specialists and professionals from related fields.

A doctor's sharing session at the conference. *Photo: Imexpharm*

As an annual scientific event, Vila 2025 focused on updated and practical topics, reflecting prominent issues in the current diagnosis, treatment, and management of respiratory diseases. Scientific reports presented by leading experts provided diverse professional perspectives, helping to clarify challenges in clinical practice at healthcare facilities.

The conference also connected the national respiratory medical community. Through discussion sessions and professional exchanges, the conference facilitated doctors sharing practical experiences, strengthening cooperation, and collectively working towards the goal of improving the quality of sustainable patient care.

Nguyen Dang Nam (left), Marketing Manager, with Imexpharm personnel at Vila 2025. *Photo: Imexpharm*

Participating in the event, Imexpharm not only served as a sponsor but also directly introduced treatment solutions through its exhibition booth, professional materials, and scientific content. This also provided an opportunity for the company to engage with doctors, discussing practical treatment needs and updating on new trends in clinical practice.

Within the conference framework, the company introduced a portfolio of high-tech antibiotic products manufactured according to EU-GMP standards. Notably, this included the product line containing the active ingredient Colistin, available in various formulations such as lyophilized powder for injection and nebulization. These offerings aim to support medical teams with more suitable treatment protocol options for hospital-acquired infections.

Product research and development at Imexpharm's EU-GMP certified pharmaceutical factory. *Photo: Imexpharm*

"Through its participation in Vila 2025, Imexpharm reaffirms its commitment to accompanying the medical community in sharing solutions and continues to pursue its goal of providing highly effective solutions for public health", a company representative stated.

The Dan